We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.44%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$256M
AUM Growth
-$27.3M
Cap. Flow
-$13M
Cap. Flow %
-5.06%
Top 10 Hldgs %
49.1%
Holding
75
New
10
Increased
14
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.88M
2
SHPG
Shire pic
SHPG
+$9.33M
3
ARRY
Array Biopharma Inc
ARRY
+$5.99M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$3.81M
5
SAGE
Sage Therapeutics
SAGE
+$3.23M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$12.6M
2
ENTL
Entellus Medical, Inc. Common Stock
ENTL
+$8.32M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.06M
4
AMGN icon
Amgen
AMGN
+$6.28M
5
BIIB icon
Biogen
BIIB
+$6.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$18.3M 7.15%
205,522
+15,500
+8% +$1.49M
SHPG
2
DELISTED
Shire pic
SHPG
$14.8M 5.77%
99,000
+67,800
+217% +$9.33M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$13.9M 5.42%
851,500
+374,000
+78% +$5.99M
NBIX icon
4
Neurocrine Biosciences
NBIX
$15.8B
$12.8M 4.98%
154,000
+117,000
+316% +$9.88M
BIIB icon
5
Biogen
BIIB
$32.7B
$12.5M 4.87%
45,608
-19,400
-30% -$6.02M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$83.1B
$12.4M 4.84%
36,030
-4,800
-12% -$1.67M
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$11.3M 4.43%
70,496
+19,000
+37% +$3.23M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$139B
$11.1M 4.34%
68,222
-7,200
-10% -$1.18M
GILD icon
9
Gilead Sciences
GILD
$185B
$9.9M 3.86%
131,284
+8,500
+7% +$676K
ADMS
10
DELISTED
Adamas Pharmaceuticals
ADMS
$8.83M 3.45%
370,000
+55,000
+17% +$1.73M
EXEL icon
11
Exelixis
EXEL
$13.7B
$8.6M 3.35%
388,334
-22,000
-5% -$608K
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$8.07M 3.15%
72,441
– –
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$7.52M 2.93%
492,930
– –
HALO icon
14
Halozyme
HALO
$12.1B
$7.03M 2.74%
358,633
+76,000
+27% +$1.47M
LGND icon
15
Ligand Pharmaceuticals
LGND
$5.68B
$6.94M 2.71%
67,326
+20,839
+45% +$2.06M
INCY icon
16
Incyte
INCY
$25.9B
$6.08M 2.37%
72,975
– –
IONS icon
17
Ionis Pharmaceuticals
IONS
$10.4B
$5.58M 2.18%
126,500
+75,000
+146% +$3.81M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$12.6B
$5.29M 2.06%
65,284
-3,100
-5% -$266K
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$31.6B
$4.38M 1.71%
36,800
– –
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
$4.01M 1.57%
76,000
– –
GTHX
21
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.81M 1.49%
103,000
+64,000
+164% +$1.71M
BLUE
22
DELISTED
bluebird bio
BLUE
$3.41M 1.33%
1,544
– –
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$3.01M 1.17%
322,436
– –
AGIO icon
24
Agios Pharmaceuticals
AGIO
$2.05B
$2.98M 1.16%
36,500
+16,500
+83% +$1.28M
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.87M 1.12%
+19,000
New +$2.79M
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2018 Portfolio in Review

As of Q1 2018, International Biotechnology Trust held 75 positions worth $256M, down 9.6% from $284M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

International Biotechnology Trust withdrew a net $13M in Q1 2018, closing 12 positions and reducing 12 holdings. Its most notable exit was Nektar Therapeutics, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Jazz Pharmaceuticals worth $2.87M.

  • International Biotechnology Trust's largest Q1 2018 buy was Jazz Pharmaceuticals: 19,000 shares worth $2.87M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q1 2018, an estimated $9.88M increase.
  • International Biotechnology Trust's biggest Q1 2018 reduction was Acadia Pharmaceuticals, cutting an estimated $8.06M.
  • International Biotechnology Trust fully exited Nektar Therapeutics in Q1 2018, selling an estimated $12.6M.
  • International Biotechnology Trust's ten largest holdings make up 49% of its $256M portfolio in Q1 2018.
  • International Biotechnology Trust opened 10 new positions and closed 12 in Q1 2018.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $256M.

Based on International Biotechnology Trust's 13F filing for Q1 2018, filed 15 May 2018.